A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen

Matthew Philip Goetz, Vera Jean Suman, James N. Ingle, Andrea M. Nibbe, Daniel W Visscher, Carol A. Reynolds, Wilma L. Lingle, Mark Erlander, Xiao Jun Ma, Dennis C. Sgroi, Edith A. Perez, Fergus J Couch

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Purpose: In the adjuvant treatment of estrogen receptor (ER) - positive breast cancer, additional markers are needed to identify women at high risk for recurrence. Experimental Design: We examined the association between the ratio of the homeobox 13 (HOXB13) to interleukin-17B receptor (IL-17BR) expression and the clinical outcomes of relapse and survival in women with ER-positive breast cancer enrolled onto a North Central Cancer Treatment Group adjuvant tamoxifen trial (NCCTG 89-30-52). Results: Tumor blocks were obtained from 211 of 256 eligible patients, and quantitative reverse transcription-PCR profiles for HOXB13 and IL-17BR were obtained from 206 patients. The cut point for the two-gene log 2(expression ratio) that best discriminated clinical outcome (recurrence and survival) was selected and identified women with significantly worse relapse-free survival (RFS), disease-free survival (DFS), and overall survival (OS), independent of standard prognostic markers. The cut point differed as a function of nodal status [node negative (59th percentile) versus node positive (90th percentile)]. In the node-positive cohort (n = 86), the HOXB13/IL-17BR ratio was not associated with relapse or survival. In contrast, in the node-negative cohort (n = 130), a high HOXB13/IL-17BR ratio was associated with significantly worse RFS [hazard ratio (HR), 1.98; P = 0.031], DFS (HR, 2.03; P = 0.015), and OS (HR, 2.4; P = 0.014), independent of standard prognostic markers. Conclusion: A high HOXB13/IL-17BR expression ratio is associated with increased relapse and death in patients with resected node-negative, ER-positive breast cancer treated with tamoxifen and may identify patients in whom alternative therapies should be studied.

Original languageEnglish (US)
Pages (from-to)2080-2087
Number of pages8
JournalClinical Cancer Research
Volume12
Issue number7 I
DOIs
StatePublished - Apr 1 2006

Fingerprint

Interleukin Receptors
Interleukin-17
Homeobox Genes
Tamoxifen
Gene Expression
Recurrence
Survival
Estrogen Receptors
Breast Neoplasms
Disease-Free Survival
Complementary Therapies
Reverse Transcription
Neoplasms
Research Design
Polymerase Chain Reaction
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. / Goetz, Matthew Philip; Suman, Vera Jean; Ingle, James N.; Nibbe, Andrea M.; Visscher, Daniel W; Reynolds, Carol A.; Lingle, Wilma L.; Erlander, Mark; Ma, Xiao Jun; Sgroi, Dennis C.; Perez, Edith A.; Couch, Fergus J.

In: Clinical Cancer Research, Vol. 12, No. 7 I, 01.04.2006, p. 2080-2087.

Research output: Contribution to journalArticle

Goetz, Matthew Philip ; Suman, Vera Jean ; Ingle, James N. ; Nibbe, Andrea M. ; Visscher, Daniel W ; Reynolds, Carol A. ; Lingle, Wilma L. ; Erlander, Mark ; Ma, Xiao Jun ; Sgroi, Dennis C. ; Perez, Edith A. ; Couch, Fergus J. / A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 7 I. pp. 2080-2087.
@article{77e76c1b01004e90a4f6091fd3d7b6de,
title = "A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen",
abstract = "Purpose: In the adjuvant treatment of estrogen receptor (ER) - positive breast cancer, additional markers are needed to identify women at high risk for recurrence. Experimental Design: We examined the association between the ratio of the homeobox 13 (HOXB13) to interleukin-17B receptor (IL-17BR) expression and the clinical outcomes of relapse and survival in women with ER-positive breast cancer enrolled onto a North Central Cancer Treatment Group adjuvant tamoxifen trial (NCCTG 89-30-52). Results: Tumor blocks were obtained from 211 of 256 eligible patients, and quantitative reverse transcription-PCR profiles for HOXB13 and IL-17BR were obtained from 206 patients. The cut point for the two-gene log 2(expression ratio) that best discriminated clinical outcome (recurrence and survival) was selected and identified women with significantly worse relapse-free survival (RFS), disease-free survival (DFS), and overall survival (OS), independent of standard prognostic markers. The cut point differed as a function of nodal status [node negative (59th percentile) versus node positive (90th percentile)]. In the node-positive cohort (n = 86), the HOXB13/IL-17BR ratio was not associated with relapse or survival. In contrast, in the node-negative cohort (n = 130), a high HOXB13/IL-17BR ratio was associated with significantly worse RFS [hazard ratio (HR), 1.98; P = 0.031], DFS (HR, 2.03; P = 0.015), and OS (HR, 2.4; P = 0.014), independent of standard prognostic markers. Conclusion: A high HOXB13/IL-17BR expression ratio is associated with increased relapse and death in patients with resected node-negative, ER-positive breast cancer treated with tamoxifen and may identify patients in whom alternative therapies should be studied.",
author = "Goetz, {Matthew Philip} and Suman, {Vera Jean} and Ingle, {James N.} and Nibbe, {Andrea M.} and Visscher, {Daniel W} and Reynolds, {Carol A.} and Lingle, {Wilma L.} and Mark Erlander and Ma, {Xiao Jun} and Sgroi, {Dennis C.} and Perez, {Edith A.} and Couch, {Fergus J}",
year = "2006",
month = "4",
day = "1",
doi = "10.1158/1078-0432.CCR-05-1263",
language = "English (US)",
volume = "12",
pages = "2080--2087",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7 I",

}

TY - JOUR

T1 - A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen

AU - Goetz, Matthew Philip

AU - Suman, Vera Jean

AU - Ingle, James N.

AU - Nibbe, Andrea M.

AU - Visscher, Daniel W

AU - Reynolds, Carol A.

AU - Lingle, Wilma L.

AU - Erlander, Mark

AU - Ma, Xiao Jun

AU - Sgroi, Dennis C.

AU - Perez, Edith A.

AU - Couch, Fergus J

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Purpose: In the adjuvant treatment of estrogen receptor (ER) - positive breast cancer, additional markers are needed to identify women at high risk for recurrence. Experimental Design: We examined the association between the ratio of the homeobox 13 (HOXB13) to interleukin-17B receptor (IL-17BR) expression and the clinical outcomes of relapse and survival in women with ER-positive breast cancer enrolled onto a North Central Cancer Treatment Group adjuvant tamoxifen trial (NCCTG 89-30-52). Results: Tumor blocks were obtained from 211 of 256 eligible patients, and quantitative reverse transcription-PCR profiles for HOXB13 and IL-17BR were obtained from 206 patients. The cut point for the two-gene log 2(expression ratio) that best discriminated clinical outcome (recurrence and survival) was selected and identified women with significantly worse relapse-free survival (RFS), disease-free survival (DFS), and overall survival (OS), independent of standard prognostic markers. The cut point differed as a function of nodal status [node negative (59th percentile) versus node positive (90th percentile)]. In the node-positive cohort (n = 86), the HOXB13/IL-17BR ratio was not associated with relapse or survival. In contrast, in the node-negative cohort (n = 130), a high HOXB13/IL-17BR ratio was associated with significantly worse RFS [hazard ratio (HR), 1.98; P = 0.031], DFS (HR, 2.03; P = 0.015), and OS (HR, 2.4; P = 0.014), independent of standard prognostic markers. Conclusion: A high HOXB13/IL-17BR expression ratio is associated with increased relapse and death in patients with resected node-negative, ER-positive breast cancer treated with tamoxifen and may identify patients in whom alternative therapies should be studied.

AB - Purpose: In the adjuvant treatment of estrogen receptor (ER) - positive breast cancer, additional markers are needed to identify women at high risk for recurrence. Experimental Design: We examined the association between the ratio of the homeobox 13 (HOXB13) to interleukin-17B receptor (IL-17BR) expression and the clinical outcomes of relapse and survival in women with ER-positive breast cancer enrolled onto a North Central Cancer Treatment Group adjuvant tamoxifen trial (NCCTG 89-30-52). Results: Tumor blocks were obtained from 211 of 256 eligible patients, and quantitative reverse transcription-PCR profiles for HOXB13 and IL-17BR were obtained from 206 patients. The cut point for the two-gene log 2(expression ratio) that best discriminated clinical outcome (recurrence and survival) was selected and identified women with significantly worse relapse-free survival (RFS), disease-free survival (DFS), and overall survival (OS), independent of standard prognostic markers. The cut point differed as a function of nodal status [node negative (59th percentile) versus node positive (90th percentile)]. In the node-positive cohort (n = 86), the HOXB13/IL-17BR ratio was not associated with relapse or survival. In contrast, in the node-negative cohort (n = 130), a high HOXB13/IL-17BR ratio was associated with significantly worse RFS [hazard ratio (HR), 1.98; P = 0.031], DFS (HR, 2.03; P = 0.015), and OS (HR, 2.4; P = 0.014), independent of standard prognostic markers. Conclusion: A high HOXB13/IL-17BR expression ratio is associated with increased relapse and death in patients with resected node-negative, ER-positive breast cancer treated with tamoxifen and may identify patients in whom alternative therapies should be studied.

UR - http://www.scopus.com/inward/record.url?scp=33646255471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646255471&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-1263

DO - 10.1158/1078-0432.CCR-05-1263

M3 - Article

C2 - 16609019

AN - SCOPUS:33646255471

VL - 12

SP - 2080

EP - 2087

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7 I

ER -